| 產品名稱 |
7E11C5 [7E11-C5] |
| 商品貨號 |
B163829 |
| Organism |
Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type |
hybridoma: B lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
Cancer |
| Strain |
Strain:? BALB/c (B cell); BALB/c (myeloma) |
| Applications |
The antibody reacts selectively with cells from both normal and neoplastic prostatic epithelium. |
| Storage Conditions |
liquid nitrogen vapor temperature |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Derivation |
Animals were immunized with live LNCaP cells and purified plasma membranes from LNCaP cells. Spleen cells were fused with P3X63Ag8.653 myeloma cells. |
| Clinical Data |
The antigen recognized by 7E11C5 appears to be present in sera from patients with prostate cancer. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against human prostate cancer antigen |
| Cellular Products |
immunoglobulin; monoclonal antibody; against human prostate cancer antigen |
| Tumorigenic |
Yes |
| Effects |
Yes, forms ascites in pristane primed BALB/c mice |
| Comments |
Animals were immunized with live LNCaP cells and purified plasma membranes from LNCaP cells. Spleen cells were fused with P3X63Ag8.653 myeloma cells. The antibody reacts selectively with cells from both normal and neoplastic prostatic epithelium. By immunofluorescence staining, the reaction was much stronger with neoplastic than normal epithelium. The antigen recognized by 7E11C5 appears to be present in sera from patients with prostate cancer. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing |
Protocol: Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. Medium Renewal: Every 2 to 3 days |
| Cryopreservation |
Freeze medium: Complete growth medium, 90%; DMSO, 10% Storage temperature: liquid nitrogen vapor temperature |
| Culture Conditions |
Temperature: 37.0°C |
| Isotype |
IgG1 |
| Name of Depositor |
Cytogen Corporation |
| Deposited As |
mouse (B cell); mouse (myeloma) |
| U.S. Patent Number |
|
| References |
Horoszewicz JS. Hybridoma and monoclonal antibody 9H10-A4 specific to an antigen of LNCaP cells. US Patent 5,578,484 dated Nov 26 1996
Horoszewicz JS. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. US Patent 5,162,504 dated Nov 10 1992
|
